Adhesive Intestinal Obstruction Clinical Trial
Official title:
Prospective Multicenter Trial for Anti-adhesion Effect of GUARDIX-SGⓇ Following Radical Gastrectomy in Patients With Gastric Cancer.
This study is to evaluate the efficacy of GUARDIX-SGⓇ for patients with gastrectomy in Korea and the investigators hypothesized applying of adhesive preventing agent would reduce incidence of adhesive obstruction after gastrectomy.
Adhesive bowel obstruction is relatively often complication in patients after abdominal
surgery
Gastric cancer is the most frequent cancer in Korea.
The incidence of adhesive bowel obstruction would be increased in patients with gastric
cancer, especially associated radical lymphadenectomy.
The causes of postoperative adhesive obstruction include adhesion of the wound, adhesion of
small intestine to small intestine, adhesion of the small intestine to other abdominal
organs, and internal hernia.
Several studies reported efficacy of adhesive preventing agent after colorectal resection.
Gastrectomy is associated with a high risk (incidence, 11.7%-38.5%) of bowel obstruction.
To date, however, no randomized study has shown that GUARDIX-SGⓇ reduces the rate of small
bowel obstruction after gastrectomy with radical lymphadenectomy for gastric cancer.
;